← Back to Search

Tc99m-MAA for Lung Cancer

Phase 1
Recruiting
Led By Eric Wehrenberg-Klee, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will help researchers determine if a particle called macro-aggregated albumin (MAA) can be used to estimate the dose of radiation to tumor and adjacent structures. MAA is labelled with technetium 99m (Tc99m).

Who is the study for?
This trial is for adults with active lung cancer who have coughed up blood and are undergoing bronchial artery embolization. Participants must not be nursing, women should either not be able to bear children or have a negative pregnancy test, and all must consent to the study procedures.Check my eligibility
What is being tested?
The study tests Tc99m-MAA's use in dosimetry planning by injecting it during bronchial embolization. It aims to estimate radiation doses that tumors and nearby tissues might receive in future treatments but offers no direct therapeutic benefit now.See study design
What are the potential side effects?
Since Tc99m-MAA is used for imaging rather than treatment, significant side effects aren't expected from this agent itself. However, standard risks associated with bronchial artery embolization may still apply.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Calculation of Tc99m-MAA uptake within the tumor and surrounding structures (radioactivity concentration)
Secondary outcome measures
Number of patients experiencing immediate post-procedural adverse events associated with bronchial artery administration of Tc99m-MAA
Abdomen

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tc99m-MAAExperimental Treatment1 Intervention
Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof. Administration will occur over a period of 30-240 seconds

Find a Location

Who is running the clinical trial?

BTG International Inc.OTHER
42 Previous Clinical Trials
3,062 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,939 Previous Clinical Trials
13,199,505 Total Patients Enrolled
Eric Wehrenberg-Klee, MDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital, Massachusetts General Physicians Organization Inc
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning
Eric Wehrenberg-Klee, MD 2020. "Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04105283.
All > Lung Cancer Boston
~0 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top